The University of Cambridge in the UK has begun a clinical trial to investigate the potential of deferiprone for treating patients with neuroferritinopathy, a rare genetic brain disorder.

For the new clinical trial, led by the University of Cambridge, an existing drug, deferiprone, will be given to 40 patients, who will take the medicine for a year. Deferiprone is already used to ...